Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383474 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
A Phase 1 study of Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and Adult Acute Basophilic Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00383474 is a Phase 1 study of Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and Adult Acute Basophilic Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 201-participant average among 5 other Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00383474, a Phase 1 study of Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and Adult Acute Basophilic Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in treating patients with acute leukemia or chronic myelogenous leukemia in blast phase. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer cells.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
- DRUG Bortezomib
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383474
The ClinicalTrials.gov registry entry for NCT00383474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 201-participant average among 5 other Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 trials with a reported enrollment target (83% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00383474 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00383474 about?
NCT00383474 is a clinical study titled "Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase". This phase I trial is studying the side effects and best dose of tipifarnib and bortezomib in treating patients with acute leukemia or chronic myelogenous leukemia in blast phase. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Gi...
What is the current status of trial NCT00383474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2006-08. Estimated completion is 2012-06.
What conditions does trial NCT00383474 study?
This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Basophilic Leukemia, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Eosinophilic Leukemia, Adult Acute Monoblastic Leukemia.
What interventions are being tested in trial NCT00383474?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00383474?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00383474 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
COMPLETED · Phase 1
-
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
All registered trials for this condition
Adult Acute Basophilic Leukemia
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.